EUVIMEDEUVIMED entdecken
Crossref

High cost of chemotherapy for gynecologic malignancies

Nobutaka Takahashi iD, Toshiyuki Seki, Keita Sasaki iD, Ryunosuke Machida, Mitsuya Ishikawa, Mayu Yunokawa iD, Ayumu Matsuoka, Masahiro Kagabu, Satoshi Yamaguchi, Kengo Hiranuma, Junki Ohnishi, Toyomi Sato

Japanese Journal of Clinical Oncology · 2024

DOI: 10.1093/jjco/hyae089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Nobutaka Takahashi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Genital Neoplasms, Female. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Cancer Center Research and Development Funds, National Federation of Health Insurance Societies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognosis of gynecological malignancies has improved with the recent advent of molecularly targeted drugs and immune checkpoint inhibitors. However, these drugs are expensive and contribute to the increasing costs of medical care.

Methods

The Japanese Clinical Oncology Group (JCOG) Health Economics Committee conducted a questionnaire survey of JCOG-affiliated facilities from July 2021 to June 2022 to assess the prevalence of high-cost regimens.

Results

A total of 57 affiliated facilities were surveyed regarding standard regimens for advanced ovarian and cervical cancers for gynecological malignancies. Responses were obtained from 39 facilities (68.4%) regarding ovarian cancer and 37 (64.9%) concerning cervical cancer, with respective case counts of 854 and 163. For ovarian cancer, 505 of 854 patients (59.1%) were treated with regimens that included PARP inhibitors, costing >500 000 Japanese yen monthly, while 111 patients (13.0%) received treatments that included bevacizumab, with costs exceeding 200 000 Japanese yen monthly. These costs are ~20 and ~10 times higher than those of the conventional regimens, respectively. For cervical cancer, 79 patients (48.4%) were treated with bevacizumab regimens costing >200 000 Japanese yen per month, ~10 times the cost of conventional treatments.

Conclusions

In this survey, >70% of patients with ovarian cancer were treated with regimens that included poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors or bevacizumab; ~50% of patients with cervical cancer were treated with regimens containing bevacizumab. These treatments were ~10 and ~20 times more expensive than conventional regimens, respectively. These findings can inform future health economics studies, particularly in assessing cost-effectiveness and related matters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genital Neoplasms, FemaleHumansFemaleUterine Cervical NeoplasmsJapanSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsPoly(ADP-ribose) Polymerase InhibitorsBevacizumabDrug CostsOvarian NeoplasmsAntineoplastic AgentsHealth Care Costs

Stichwörter der Autor:innen

carcinomacost-effectivenessgynecologic oncologymolecular targeted therapypoly (adenosine diphosphate-ribose) polymerase inhibitors

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBevacizumabAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
  • Japan Clinical Oncology Group Data Centre/Operations Office, National Cancer Centre Hospital, Tokyo, Japan.
  • Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Gynecologic Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.

ORCID-Profile: Nobutaka Takahashi, Keita Sasaki, Mayu Yunokawa

Förderung

  • National Cancer Center Research and Development Funds
  • National Federation of Health Insurance Societies

Zitieren

APA

Takahashi, N., Seki, T., Sasaki, K., Machida, R., Ishikawa, M., Yunokawa, M., Matsuoka, A., Kagabu, M., Yamaguchi, S., Hiranuma, K., Ohnishi, J., & Sato, T. (2024). High cost of chemotherapy for gynecologic malignancies. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae089

Vancouver

Takahashi N, Seki T, Sasaki K, Machida R, Ishikawa M, Yunokawa M, et al. High cost of chemotherapy for gynecologic malignancies. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae089

BibTeX
@article{Takahashi2024,
  author = {Takahashi, Nobutaka and Seki, Toshiyuki and Sasaki, Keita and Machida, Ryunosuke and Ishikawa, Mitsuya and Yunokawa, Mayu and Matsuoka, Ayumu and Kagabu, Masahiro and Yamaguchi, Satoshi and Hiranuma, Kengo and Ohnishi, Junki and Sato, Toyomi},
  title = {High cost of chemotherapy for gynecologic malignancies},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1093/jjco/hyae089}
}
Kostenlos starten →